September 28, 2016 10:09 AM EDT
R&D
Pharma

Hub ap­peal: As­traZeneca is mar­shal­ing 350-plus R&D troops in new South San Fran­cis­co cam­pus

John Carroll

Editor & Founder

In bio­phar­ma, the big glob­al hubs have be­come ir­re­sistible at­trac­tions as tro­phy lo­ca­tions suck in thou­sands of R&D jobs from the gi­ants as well as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times